Novo Nordisk Juggles Share Buybacks and Pipeline Hype as CagriSema Data Approaches

Danish pharma giant unveils REIMAGINE Phase 3 results for CagriSema, runs $1.6B buyback, as stock tumbles 39% amid pipeline doubts and Lilly competition.

Novo Nordisk faces a defining week that will test both its financial discipline and its pipeline credibility. The Danish pharma giant kicks off its presence at the American Diabetes Association’s Scientific Sessions in New Orleans on 5 June, unveiling 40 abstracts that include the pivotal Phase 3 REIMAGINE data for CagriSema. At the same time, it is plowing on with a 15 billion DKK share repurchase programme worth roughly 0.8% of total equity – a signal that management is determined to keep capital returning to shareholders even as the stock languishes near 38.55 euros, down 39% over the past year.

The REIMAGINE 1, 2 and 3 trials evaluate CagriSema, a fixed-dose combination of semaglutide and the long-acting amylin analogue cagrilintide, in patients with type 2 diabetes. Investors are looking for evidence that the combination can beat existing monotherapies on glucose control and weight loss. In parallel, the group will release Phase 2 data on Zenagamtide, a weekly injectable GLP-1/amylin candidate that forms part of the broader effort to diversify beyond the blockbuster semaglutide franchise. An R&D investor day on 7 June will offer deeper detail on the clinical results and a clearer regulatory timeline for CagriSema, which is expected to face an FDA decision in the fourth quarter of 2026.

While the pipeline narrative dominates the headlines, the buyback programme provides a quieter but steady undercurrent of capital discipline. The current tranche, launched in May, has a volume of roughly 11.2 billion DKK and is set to run until early February 2027. In the latest reported week, Novo Nordisk repurchased 3.13 million B-shares for 913.3 million DKK. Since the start of the full programme in February 2026, it has bought back 17.89 million shares at an average price of 263.47 DKK, spending a total of 4.71 billion DKK. The company now holds 35.07 million B-shares, or 0.8% of the total capital. Reducing the float mechanically lifts earnings per share, offering some support to a stock that has been under heavy pressure.

The share price decline reflects more than just market jitters. The stock trades at a price-to-earnings ratio of around 11, and analysts characterise 2026 as a transition year. US pricing headwinds, together with doubts about the competitive strength of the pipeline, have weighed on the valuation. Eli Lilly’s oral GLP-1 drug Foundayo entered key US formularies on 1 June, eroding the first-mover edge that Novo Nordisk’s oral Wegovy tablet enjoyed after its own launch earlier in the year. Despite that, Novo Nordisk still boasts a gross margin of more than 80%, giving it some leeway to compete on pricing if necessary.

The dividend yield currently stands at 3.84%, which adds a modest income component to an equity that has shed nearly 40% in twelve months. The buyback programme does not fix the operational challenges, but it does send a clear message that management sees the current valuation as attractive enough to allocate capital toward its own shares. The market reaction in the coming days will depend heavily on whether the REIMAGINE data can restore confidence in the pipeline’s potential to fend off rivals like Lilly.

With the FDA decision on CagriSema still months away, and the buyback programme grinding on through early next year, Novo Nordisk is navigating a period of dual signals: financial strength on the balance sheet, but deep uncertainty about its competitive future. The conference in New Orleans will go a long way toward determining which signal investors choose to believe.